BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Szpakowska M, Meyrath M, Reynders N, Counson M, Hanson J, Steyaert J, Chevigné A. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Biochemical Pharmacology 2018;153:299-309. [DOI: 10.1016/j.bcp.2018.03.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Bayrak A, Mohr F, Kolb K, Szpakowska M, Shevchenko E, Dicenta V, Rohlfing AK, Kudolo M, Pantsar T, Günther M, Kaczor AA, Poso A, Chevigné A, Pillaiyar T, Gawaz M, Laufer SA. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation. J Med Chem 2022. [PMID: 36150079 DOI: 10.1021/acs.jmedchem.2c01198] [Reference Citation Analysis]
2 Yen Y, Schafer CT, Gustavsson M, Eberle SA, Dominik PK, Deneka D, Zhang P, Schall TJ, Kossiakoff AA, Tesmer JJG, Handel TM. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Sci Adv 2022;8:eabn8063. [DOI: 10.1126/sciadv.abn8063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Duval V, Alayrac P, Silvestre J, Levoye A. Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases. Front Endocrinol 2022;13:906586. [DOI: 10.3389/fendo.2022.906586] [Reference Citation Analysis]
4 Passman AM, Strauss RP, McSpadden SB, Finch-Edmondson M, Andrewartha N, Woo KH, Diepeveen LA, Zhao W, Fernández-Irigoyen J, Santamaría E, Medina-Ruiz L, Szpakowska M, Chevigné A, Park H, Carlessi R, Tirnitz-Parker JEE, Blanco JR, London R, Callus BA, Elsegood CL, Baker MV, Martínez A, Yeoh GCT, Ochoa-Callejero L. Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. Cancers (Basel) 2021;13:4935. [PMID: 34638423 DOI: 10.3390/cancers13194935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sigmund EC, Baur L, Schineis P, Arasa J, Collado-Diaz V, Vranova M, Stahl RAK, Thelen M, Halin C. Lymphatic endothelial-cell expressed ACKR3 is dispensable for postnatal lymphangiogenesis and lymphatic drainage function in mice. PLoS One 2021;16:e0249068. [PMID: 33857173 DOI: 10.1371/journal.pone.0249068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Meyrath M, Palmer CB, Reynders N, Vanderplasschen A, Ollert M, Bouvier M, Szpakowska M, Chevigné A. Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7. ACS Pharmacol Transl Sci 2021;4:813-23. [PMID: 33860204 DOI: 10.1021/acsptsci.1c00006] [Reference Citation Analysis]
7 Chevigné A, Janji B, Meyrath M, Reynders N, D'Uonnolo G, Uchański T, Xiao M, Berchem G, Ollert M, Kwon YJ, Noman MZ, Szpakowska M. CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6. Cancers (Basel) 2021;13:1054. [PMID: 33801414 DOI: 10.3390/cancers13051054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Matti C, D'Uonnolo G, Artinger M, Melgrati S, Salnikov A, Thelen S, Purvanov V, Strobel TD, Spannagel L, Thelen M, Legler DF. CCL20 is a novel ligand for the scavenging atypical chemokine receptor 4. J Leukoc Biol 2020;107:1137-54. [PMID: 32533638 DOI: 10.1002/JLB.2MA0420-295RRR] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
9 Kouzeli A, Collins PJ, Metzemaekers M, Meyrath M, Szpakowska M, Artinger M, Struyf S, Proost P, Chevigne A, Legler DF, Eberl M, Moser B. CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems. Front Immunol 2020;11:561404. [PMID: 33123134 DOI: 10.3389/fimmu.2020.561404] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Arendt V, Amand M, Iserentant G, Lemaire M, Masquelier C, Ndayisaba GF, Verhofstede C, Karita E, Allen S, Chevigné A, Schmit JC, Bercoff DP, Seguin-Devaux C. Predominance of the heterozygous CCR5 delta-24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface. J Int AIDS Soc 2019;22:e25384. [PMID: 31486251 DOI: 10.1002/jia2.25384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Meyrath M, Szpakowska M, Zeiner J, Massotte L, Merz MP, Benkel T, Simon K, Ohnmacht J, Turner JD, Krüger R, Seutin V, Ollert M, Kostenis E, Chevigné A. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nat Commun 2020;11:3033. [PMID: 32561830 DOI: 10.1038/s41467-020-16664-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
12 Meyrath M, Reynders N, Uchański T, Chevigné A, Szpakowska M. Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22. J Leukoc Biol 2021;109:373-6. [PMID: 32480426 DOI: 10.1002/JLB.2AB0520-275R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Moussouras NA, Hjortø GM, Peterson FC, Szpakowska M, Chevigné A, Rosenkilde MM, Volkman BF, Dwinell MB. Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21. Biochemistry 2020;59:1338-50. [PMID: 32182428 DOI: 10.1021/acs.biochem.0c00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Guo K, Feng G, Yan Q, Sun L, Zhang K, Shen F, Shen M, Ruan S. CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members. Mol Med Rep 2019;20:4791-802. [PMID: 31702806 DOI: 10.3892/mmr.2019.10784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Neirinckx V, Hau AC, Schuster A, Fritah S, Tiemann K, Klein E, Nazarov PV, Matagne A, Szpakowska M, Meyrath M, Chevigné A, Schmidt MHH, Niclou SP. The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. Neurooncol Adv 2019;1:vdz024. [PMID: 32642659 DOI: 10.1093/noajnl/vdz024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Gilbert W, Bragg R, Elmansi AM, McGee-Lawrence ME, Isales CM, Hamrick MW, Hill WD, Fulzele S. Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology. Cytokine 2019;123:154783. [PMID: 31336263 DOI: 10.1016/j.cyto.2019.154783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
17 Reynders N, Abboud D, Baragli A, Noman MZ, Rogister B, Niclou SP, Heveker N, Janji B, Hanson J, Szpakowska M, Chevigné A. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells 2019;8:E613. [PMID: 31216755 DOI: 10.3390/cells8060613] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
18 Koenen J, Bachelerie F, Balabanian K, Schlecht-Louf G, Gallego C. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System. Mol Pharmacol 2019;96:809-18. [PMID: 31040166 DOI: 10.1124/mol.118.115329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]